AstraZeneca (AZN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.00
- Estimate
- $1.15
- Surprise
- -12.7%
- Score at report (before → after)
- 5.7 → 5.7/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
AstraZeneca (AZN) missed the $1.15 estimate with adjusted EPS of $1.00 — a large 12.7% shortfall. TrendMatrix's engine moved from Buy (Wait) (5.7/10) to Hold at 5.7/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates AZN Hold at 5.7/10.
3 of the last 4 quarters beat the estimate; this quarter's -12.7% surprise compares with a -0.4% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Analyst target reached - limited upside remaining
- Euphoria warning: extreme positivity (+0.90) + overbought RSI 80
- Weak growth
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $186.65
- Stop
- $176.63
The stock trades at 27.9× trailing but 16.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 80 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.8× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-31 — shown for context, not personalized investment advice.
AZN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $289.48B
- P/E (fwd)
- 16.5
- P/E (ttm)
- 27.9
- 52-week range
- $153.41–$212.71
- Off 52-week high
- 12.3%
- RSI (14)
- 80
- Volume vs avg
- 1.77×
- Score today
- 5.7/10